CRISPR-based mouse model for VHL-deficient clear cell kidney cancer shows promise, suggested by Yüksel Ürün
Yüksel Ürün shared an article by Laura A Stransky on X:
“A new CRISPR-based mouse model for VHL-deficient clear cell kidney cancer shows promise.
Though not fully HIF2-dependent, challenges remain in mimicking human tumor behavior at PNAS News, Kaelin Lab, Signoretti Lab, Dana-Farber Cancer Institute and Eliezer M Van Allen.”
Authors: Laura A Stransky, Wenhua Gao, Laura S Schmidt, Kevin Bi, Christopher J Ricketts, Vijyendra Ramesh, Amy James, Simone Difilippantonio, Lilia Ileva, Joseph D Kalen, Baktiar Karim, Albert Jeon, Tamara Morgan, Andrew C Warner, Sevilay Turan, Joanne Unite, Bao Tran, Sulbha Choudhari, Yongmei Zhao, Douglas E Linn, Changhong Yun, Sripriya Dhandapani, Vaishali Parab, Elaine M Pinheiro, Nicole Morris, Lixia He, Sean M Vigeant, Jean-Christophe Pignon, Maura Sticco-Ivins, Sabina Signoretti, Eliezer M Van Allen, W Marston Linehan and William G Kaelin Jr.
Source: Yüksel Ürün/X
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023